-
Eli Lilly Says It Will Launch 20 New Products Through 2023
Tuesday, May 24, 2016 - 9:41am | 306Read More...Eli Lilly and Co (NYSE: LLY) detailed in a presentation to the investment community its outlook for new product launches through 2023. Eli Lilly said that it has the potential to launch a total of 20 new products in the 10-year period beginning in 2014 and extending through 2023. In addition, the...
-
Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance
Tuesday, January 5, 2016 - 9:13am | 188Read More...Shares of Eli Lilly and Co (NYSE: LLY) were trading lower by more than 1 percent at $81.78 early Tuesday morning after the company reported a weaker-than-expected fiscal 2016 guidance. Eli Lilly said it expects to earn $3.45 to $3.55 per share in fiscal 2016 on revenue of $20.2 billion to $20.7...
-
Eli Lilly CEO: Recent Events In China Don't Change Much
Sunday, August 16, 2015 - 1:32pm | 373Read More...The slowing of China's economy and the strength in the dollar are significantly impacting companies with substantial international presence like Eli Lilly and Co (NYSE: LLY). John Lechleiter, chairman, president and CEO of Eli Lilly, was on CNBC last Friday to discuss how the company is dealing...
-
Here's A Look At Eli Lilly's Future Pipeline
Saturday, August 15, 2015 - 10:39am | 336Read More...Eli Lilly and Co (NYSE: LLY) Chairman, President and CEO John Lechleiter was on CNBC Friday to reveal the company's upcoming drug pipeline. Here is what he shared. The Pipeline "We went through a period where we lost the patents on our four biggest products," Lechleiter began....
-
Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat
Thursday, July 23, 2015 - 1:39pm | 356Read More...Eli Lilly and Co (NYSE: LLY) came out with remarkable second-quarter numbers on Thursday. The company reported adjusted EPS of $0.90, beating consensus analysts' estimates of adjusted EPS of $0.74 by $0.16. John Lechleiter, Eli Lilly CEO, was on CNBC recently to weigh in on the numbers and...
-
Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar
Monday, February 2, 2015 - 8:43am | 341Read More...John Lechleiter, CEO at Eli Lilly and Co (NYSE: LLY), was recently on CNBC to talk about the products coming off patent and the impact of currency on the company’s top-line. Patent Expirations “It’s been a roller-coaster ride, we lost our U.S. patent on Zyprexa in 2011...
-
Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies
Monday, January 12, 2015 - 5:04pm | 341Read More...Eli Lilly and Co (NYSE: LLY) has witnessed a continuous rally since last year, up 33 percent in that time frame. Eli Lilly CEO John Lechleiter was on CNBC Monday to discuss the outlook for the healthcare sector and the new drugs that he is most excited about. "I'm optimistic about 2015...
-
News Summary
Thursday, June 10, 2010 - 12:19pm | 333Read More...See more trading ideas here The International Energy Agency (IEA), which acts as an energy watchdog for largely wealthy nations like the US, today raised its 2010 world oil-demand forecast by 60,000 barrels a day to 86.4 million barrels a day. At the same time, the Paris-based agency warned that up...
-
Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC
Friday, January 29, 2010 - 9:09am | 134Read More...Eli Lilly (NYSE: LLY) posted its Q4 EPS at $0.91, narrowly missing the market estimate of $0.92. However, it surpassed the market revenue expectation of $5.677 billion and recorded $5.93 billion in revenue. Talking with CNBC, Eli Lilly’ CEO John Lechleiter said that the company did well in 2009...
